Management of Elevated INR

Immediate Management

The American Society of Hematology/International Society on Thrombosis and Haemostasis recommends administering oral vitamin K 5 mg as the primary intervention for INR >10 without bleeding, and withholding warfarin until the INR returns to therapeutic range 1
Withhold warfarin until the INR falls below 3.5, then restart at 80% of the previous dose (20% dose reduction), as suggested by the American Society of Hematology/International Society on Thrombosis and Haemostasis guidelines 1

The American College of Chest Physicians guidelines suggest against routine vitamin K use for INR 4.5-10 without bleeding (Grade 2B), as pooled RCT data showed no difference in major bleeding, thromboembolism, or mortality between vitamin K and withholding warfarin alone 4, 5
At INR >10, the bleeding risk becomes substantial, increasing exponentially with each INR increment, with up to 75 adverse events per 100 patient-years at INR 6.5 4, 5

Recheck INR within 24-48 hours after vitamin K administration to confirm appropriate reduction, and continue monitoring every 24-48 hours until INR is stable in therapeutic range 2
When restarting warfarin, reduce the weekly total dose by 10-15% 2

High-risk features warranting more aggressive management include age >65 years, history of prior bleeding, and mechanical heart valves, as suggested by the American College of Chest Physicians guidelines 2, 5

Do not administer vitamin K intravenously unless life-threatening bleeding is present, as anaphylactic reactions occur in 3 per 100,000 IV doses, according to Praxis Medical Insights 3
Do not restart warfarin at the same dose—always reduce by at least 10-20% to prevent recurrent supratherapeutic INR, as recommended by the American Society of Hematology/International Society on Thrombosis and Haemostasis guidelines 1, 2